HIPAA Regulatory Alert: White Paper addresses DM, HIPAA concerns
A comprehensive analysis of HIPAA and its impact on disease management has concluded that the new privacy regulations will not hamper disease management programs, according to the Disease Management Association of America (DMAA) in Washington, DC.
The association’s White Paper concluded that the U.S. Department of Health and Human Services has fully safeguarded the ability of legitimate disease management programs to use and disclose protected health information for activities within the DMAA’s industry consensus of disease management.
The White Paper’s legacy
These include enrolling and engaging patients, teaching patient self-management, coordinating care, providing medication compliance guidelines and reminders, publishing outcomes data, conducting population management and risk stratification, supporting physicians and the plan of care, and promoting other disease management and population management services.
"While a lot of things in HIPAA are still unclear, disease management is not one of them. The White Paper’s legacy will be to eliminate any concern that disease management cannot coexist with strong patient privacy protections, that disease manager somehow hinder or is hindered by privacy. Neither is true, and this initiative finally proves it," says Warren Todd, DMAA’s executive director.
The document may be obtained free of charge from DMAA. See their web site at www.dmaa.org.
A comprehensive analysis of HIPAA and its impact on disease management has concluded that the new privacy regulations will not hamper disease management programs, according to the Disease Management Association of America (DMAA) in Washington, DC.You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content